CN109157554A - Chinese medicine composition, the preparation method and applications for treating whelk and verruca plana - Google Patents
Chinese medicine composition, the preparation method and applications for treating whelk and verruca plana Download PDFInfo
- Publication number
- CN109157554A CN109157554A CN201810957814.2A CN201810957814A CN109157554A CN 109157554 A CN109157554 A CN 109157554A CN 201810957814 A CN201810957814 A CN 201810957814A CN 109157554 A CN109157554 A CN 109157554A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- whelk
- extract
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 208000000260 Warts Diseases 0.000 title claims abstract description 37
- 201000010153 skin papilloma Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 241000934136 Verruca Species 0.000 title claims description 28
- 239000000284 extract Substances 0.000 claims abstract description 55
- 239000010231 banlangen Substances 0.000 claims abstract description 35
- 241000202726 Bupleurum Species 0.000 claims abstract description 19
- 241000334160 Isatis Species 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 9
- 238000000638 solvent extraction Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 3
- 150000004676 glycans Chemical class 0.000 claims description 27
- 239000005017 polysaccharide Substances 0.000 claims description 27
- 229920001282 polysaccharide Polymers 0.000 claims description 27
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 claims description 5
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 claims description 5
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 claims description 5
- 238000001256 steam distillation Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 230000004224 protection Effects 0.000 abstract description 3
- 230000036592 analgesia Effects 0.000 abstract description 2
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 2
- 239000002221 antipyretic Substances 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000001151 other effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000712461 unidentified influenza virus Species 0.000 abstract description 2
- 230000003263 anti-adenoviral effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- 235000019441 ethanol Nutrition 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 27
- 239000011347 resin Substances 0.000 description 26
- 229920005989 resin Polymers 0.000 description 26
- 229940079593 drug Drugs 0.000 description 23
- 238000010828 elution Methods 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
- 239000008367 deionised water Substances 0.000 description 14
- 229910021641 deionized water Inorganic materials 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 229930182490 saponin Natural products 0.000 description 14
- 150000007949 saponins Chemical class 0.000 description 14
- 235000017709 saponins Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 239000003729 cation exchange resin Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- -1 oral solution Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940100688 oral solution Drugs 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 201000002282 venous insufficiency Diseases 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 241001062009 Indigofera Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- VJEMOEYSQDKAQF-MJKDWHOWSA-N Saikosaponin C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2C([C@H]3[C@](C4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)O[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VJEMOEYSQDKAQF-MJKDWHOWSA-N 0.000 description 1
- VSVPCEFIECVNTB-UHFFFAOYSA-N Saikosaponin c Natural products CC1OC(OC2C(O)C(O)C(OC3CCC4(C)C(C3)C(C)(C)CC5(C)C4C=CC67OCC8(CCC(C)(C)CC68)C(O)CC57C)OC2COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C1O VSVPCEFIECVNTB-UHFFFAOYSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004046 cell surface extension Anatomy 0.000 description 1
- ZDKCXSMMRXSSDE-UHFFFAOYSA-N chikusakoside II Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)OC1COC1C(O)C(O)C(O)C(CO)O1 ZDKCXSMMRXSSDE-UHFFFAOYSA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008125 glucin Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N indirubin Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940072644 pitressin Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- VJEMOEYSQDKAQF-UHFFFAOYSA-N saikogenin E 3-O-beta-D-glucopyranosyl-(1?6)-[alpha-L-rhamnopyranosyl-(1?4)]-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)OC1COC1C(O)C(O)C(O)C(CO)O1 VJEMOEYSQDKAQF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of Chinese medicine composition for treating whelk and wart, preparation method and applications, is related to technical field of traditional Chinese medicine preparation field.The composition includes bupleurum extract and isatis root extract.Its specific preparation step are as follows: S1: the preparation of bupleurum extract, including solvent extraction, filtering, concentration；The substance of isatis root extract, including solvent extraction, filtering, concentration, purifying；S2: bupleurum extract and isatis root extract mixing.The Chinese medicine composition is used to prepare pharmaceutical preparation, functional food or cosmetics.The present invention prepares composition by bupleurum extract and isatis root extract, has gathered the anti-inflammatory, antibacterial of the two, the effect of strengthen immunity.Wherein, radix bupleuri mainly has anti-inflammatory, liver protection, antipyretic, analgesia and other effects.Radix Isatidis mainly has effects that resisiting influenza virus, anti-adenovirus activity.And the two mixing ratio its independent role therapeutic effect is more preferably, has synergistic effect.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicine preparation, and in particular to a kind of Chinese medicine composition for treating whelk and wart, system
Preparation Method and its application.
Background technique
As the saying goes " everybody has a love of beauty ", either self-confident or meeting, itself appearance neatly all seem especially heavy
It wants.Whelk and wart are the most common skin problems of adolescence, and whelk is the chronic inflammatory skin of pilosebaceous follicle
Disease, skin surface caused by being infected when wart is under body immunity by human papilloma virus HPV3 and HPV5 are benign superfluous
Biology.
Whelk, scientific name acne are a kind of chronic inflammatory skins of pilosebaceous follicle, are mainly in Head And Face, neck
And chest and back.Whelk plays the role of endocrine factors, sebum, a variety of pathogenic factors of microorganism in hair follicle, mainly by endocrine
Factor influences.Verruca plana is one kind of wart, common for proliferative skin disorders caused by human papilloma virus (HPV) infection
In exposure portions such as face, the back of the hand.
Currently, have western medicine class, Chinese patent drug class etc. in the market for treating whelk and the medicament categories of verruca plana are various,
These defects for having the drug for the treatment of whelk and verruca plana are cannot thoroughly to eradicate whelk, and treatment cycle is long, often
Often recurrence again, brings damage and financial burden to the face of patient, while causing mental suffering after healing.
Summary of the invention
(1) the technical issues of solving
In view of the deficiencies of the prior art, the present invention provides a kind of Chinese medicine composition, preparation methods for treating whelk and wart
And its application, solve the technical problem of existing whelk and treating flat wart period length.
(2) technical solution
In order to achieve the above object, the present invention is achieved by the following technical programs:
In a first aspect, providing a kind of Chinese medicine composition for treating whelk and verruca plana, including bupleurum extract and plate indigo plant
Root extract.
Preferably, saikoside content accounts for the 5~100% of total amount in the bupleurum extract.
Preferably, the saikoside includes saikosaponin a, saikoside c, saikoside d, saikoside b1, radix bupleuri
Saponin(e b2, saikoside h it is any in or it is a variety of.
Preferably, the effective component of the isatis root extract includes Banlangen Polysaccharide.
Preferably, the mixed proportion of the bupleurum extract and the isatis root extract is 3~7:3~7.
Second aspect, provides the preparation method of the Chinese medicine composition of above-mentioned treatment whelk and verruca plana, and feature exists
In specific steps are as follows:
S1: the preparation of bupleurum extract, including solvent extraction, filtering, concentration；
The substance of isatis root extract, including solvent extraction, filtering, concentration, purifying；
S2: bupleurum extract and isatis root extract mixing.
Preferably, pass through steam distillation before solvent extraction in the preparation process of the bupleurum extract.
Preferably, the raw material for extracting bupleurum extract includes stem, leaf, flower spike, fruit, rhizome or the bavin of radix bupleuri
Hu medicine materical crude slice is any one or more of.
The third aspect provides the application of the Chinese medicine composition of above-mentioned treatment whelk and verruca plana, by the Chinese medicine group
It closes object and is used to prepare pharmaceutical preparation, functional food or cosmetics.
(3) beneficial effect
The present invention provides a kind of Chinese medicine composition, preparation method and applications for treating whelk and wart.With the prior art
Compare, have it is following the utility model has the advantages that
The effective component of radix bupleuri be saponin(e, flavonoids, ethereal oil, plant alcohols, have antibacterial, it is anti-inflammatory, antiviral,
Improve effect of the body to nonspecific stimulation resistivity.Wherein saikoside includes exudation, capillary to many inflammatory processes
Vasopermeability, inflammatory mediator release, leukoplania and connective tissue proliferation etc. all have an impact；Saikoside is Na+One K+
Effective inhibitor of one ATP enzyme can cause obviously increasing for the hormones such as blood glucose, ACTH, aldosterone, pitressin, cortin, add
The metabolism of strong sugar, salt, water, while generating the effect of anti-inflammatory, antiallergy, antiulcer, antiviral etc.；Saikoside and sweet
Careless glucin inhibits Na+—K+The structure-activity relationship of one atpase activity.Saikoside is to body specific immune function and non-specificity
Immune function has certain adjustment effect.Inside and outside experiment discovery, the extension of the macrophage under saikoside stimulation are living
Killing activity intracellular, the activity of acid phosphatase of property, phagocytic, lysozyme activity and saccharomycete increase, Er Qiezeng
The receptor active of Macrophage Surface is added.Observation in vitro finds that actin is micro- in the macrophage after saikoside effect
Silk is in fine and close distribution extensively, and macrophage seemingly has the cell surface protrusion increased, flourishing golgiosome and biggish
Endochylema vacuole,
The essence and mechanism of action of Radix Isatidis heat-clearing toxin-expelling functions are that Radix Isatidis can facedown bacterium, virus, endogenous toxic material
Element etc. " exogenous poison ", and the synthesis and release of " poison of endogenous " inflammatory mediator that exogenous poison can be inhibited to induce, drop
Low LPO is horizontal, the oxygen radical removings enzymatic activity such as increased SOD, improves body to the Scavenging activity of oxygen radical and Radix Isatidis is more
Sugar has multiple biological activities, can promote immunological regulation, be a kind of ideal immunopotentiator.Banlangen Polysaccharide, indigo red,
Indigo is one of Radix Isatidis main active, all has significant anti-inflammatory treatment effect, wherein Banlangen Polysaccharide can be mentioned significantly
The level of high Serum Antibody IgG and spleen cell IFN-y enhance T, bone-marrow-derived lymphocyte stimulus index, to specific immunity and
Nospecific immunity has certain facilitation.
The present invention prepares composition by bupleurum extract and isatis root extract, has gathered the anti-inflammatory, antibacterial of the two, has increased
The effect of strong immunity.Utilize the anti-inflammatory of radix bupleuri, liver protection, antipyretic, analgesia and other effects, the resisiting influenza virus of Radix Isatidis, anti-adenopathy
The effect of cytotoxic activity.More preferably by the two mixing ratio its independent role therapeutic effect, there is synergistic effect, shorten whelk
With the treatment cycle of verruca plana.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, below will to embodiment or
Attached drawing needed to be used in the description of the prior art is briefly described, it should be apparent that, the accompanying drawings in the following description is only
Some embodiments of the present invention, for those of ordinary skill in the art, without creative efforts, also
Other drawings may be obtained according to these drawings without any creative labor.
Fig. 1 is the derivative chromatogram of PMP of Radix Isatidis standard monosaccharide mixed liquor；
Fig. 2 is the HPLC chromatogram of each saponin(e of radix bupleuri main component radix bupleuri；
Fig. 3 is the HPLC finger-print schematic diagram of the radix bupleuri extracted and Radix Isatidis mixture effective component of the invention.
Specific embodiment
In order to make the object, technical scheme and advantages of the embodiment of the invention clearer, to the technology in the embodiment of the present invention
Scheme is clearly and completely described, it is clear that and described embodiments are some of the embodiments of the present invention, rather than whole
Embodiment.Based on the embodiments of the present invention, those of ordinary skill in the art are obtained without creative efforts
The every other embodiment obtained, shall fall within the protection scope of the present invention.
It is raw materials used: to be commercially available material.
Illustrate the present invention below by embodiment is further details of.
Embodiment 1: the Chinese medicine composition for the treatment of whelk and verruca plana
1) it takes radix bupleuri medicine materical crude slice lkg, 0.4%Na0H, 50% ethyl alcohol 10L refluxing extraction 3 times, extracts 1 hour every time, decompression
Recycling design obtains extract, and water dispersion is added to dissolve, and makes aqueous solution extension rate 1:14 (with crude drug meter), big by 8LAB-8
Macroporous adsorbent resin, adsorption flow rate 3BV/h, resin column diameter height compare for 1:8, and applied sample amount is 0.125g/mL (with crude drug meter),
50% 4 times of ethanol elution resin volume cleans, and removal of impurities flow velocity is 3BV/h, and 90% 5 times of ethanol elution resin volume is washed
Separation of flow speed is 2BV/h, collects 90% ethanol eluate, and recycling design is dried under reduced pressure, as total saponins from radix bupleuri extract.Measurement
Total saponin content is 62% in total saponins from radix bupleuri extract, wherein saikosaponin a, saikosaponin C, saikoside d kind ingredient
The sum of content is 25%.
2) Radix Isatidis 20g is weighed, 300mL deionized water is added, the extraction of 90C temperature takes, extracts 2 times, each 2h；It closes 2 times and mentions
Liquid is taken, 100mL is concentrated under reduced pressure into, 280mL ethyl alcohol is added, makes concentration of alcohol 70%.10h is stood, filter paper is crossed to obtain alcohol precipitation
400mL deionized water is added with 200mL ethanol washing in object, and ultrasound is redissolved, and 60mL is concentrated under reduced pressure into, filter off molten object to get
Concentration about 0.33g/mL (based on crude drug) Banlangen Polysaccharide liquid.
Above-mentioned steps 2) during, pretreated macroporous type Weak-acid cation exchange resin is with 1mol/L hydrochloric acid solution with 2
The elution of~3 times of column volumes 2 hours, deionized water rinse pillar to proximity；Then again with lmol/L NaOH solution with 2~
The elution of 3 times of column volumes 2 hours, deionized water rinse pillar to neutrality is connect, finally with 1mol/L hydrochloric acid solution with 2~3 times
The elution of column volume 2 hours, deionized water rinse pillar to connecing neutrality.
Macroporous type Weak-acid cation exchange resin of the present invention can regenerate, and be in method, using 1mol/Li acid
For solution with elution 2 hours of 2~3 times of column volumes, deionized water rinsed pillar to close neutrality: then it is molten with 1mol/NaOH again
For liquid with elution 2 hours of 2-3 times of column volume, deionized water rinsed pillar to close neutrality；Finally with 1mol/ hydrochloric acid solution with 2
The elution of~3 times of column volumes 2 hours, deionized water rinse pillar to close neutrality.
Saikoside extracting solution and Banlangen Polysaccharide extracting solution are mixed in 3:7 ratio is corresponding, are used to prepare pharmaceutical preparation
Or functional food, cosmetics, gained drug or functional food or cosmetics can be capsule, tablet, pill, particle
Agent, oral solution, syrup, electuary, vina, paste, powder, beverage, injection, emulsifiable paste or lotion etc..
Embodiment 2: the Chinese medicine composition for the treatment of whelk and verruca plana
1) radix bupleuri medicine materical crude slice l0kg, 0.5%Na0H, 55% ethyl alcohol 15L is taken, refluxing extraction 3 times, is extracted 1.5 hours every time,
Recycling design, extract add water dispersion to dissolve, and make aqueous solution extension rate 1:12 (with crude drug meter), big by 6L AB-8
Macroporous adsorbent resin, adsorption flow rate 4BV/h, resin column diameter height compare for 1:7, and applied sample amount is 0.16g/mL (with crude drug meter),
45% 4 times of ethanol elution resin volume cleans, and removal of impurities flow velocity is 2BV/h, 85% 4 times of ethanol elution resin volume, elution
Flow velocity is 2BV/h, collects 85% ethanol eluate, and recycling design is dried under reduced pressure, as total saponins from radix bupleuri extract.Measure bavin
The total soap of Hu saponin content in extract is 65%, and wherein radix bupleuri soap has a, saikoside c, saikoside d three kinds of ingredients
The sum of content is 27%.
2) Radix Isatidis 20g is weighed, 300mL deionized water is added, the extraction of 90C temperature takes, extracts 2 times, each 2h；Merge 2 times
Extracting solution is concentrated under reduced pressure into 100mL, and 280mL ethyl alcohol is added, makes Z determining alcohol 70%.10h is stood, alcohol is obtained by filtration in filter paper
400mL deionized water is added with 200mL ethanol washing in hypostasis, and ultrasound is redissolved, and 60mL is concentrated under reduced pressure into, and filters off insoluble matter,
Up to concentration about 0.33g/mL (based on crude drug) Banlangen Polysaccharide liquid, add lmol/L NaOH solution and lmol/L HCI solution tune
Saving Banlangen Polysaccharide crude liquid pH is 5.
3) it takes by pretreated macroporous type Weak-acid cation exchange resin, parent is polyacrylic acid, and functional group is
Carboxyl filters off moisture content, weighs 3g and be placed in resins exchange device, and in the ratio of every gram of resin 20mL Banlangen Polysaccharide liquid, step is added
2) pH obtained is 5, and concentration about 5g/m polysaccharide crude liquid is placed in water bath with thermostatic control shaking table, 50 DEG C, after 100r/min vibrates 1h,
Resin is filtered off, the albumen and pigment in separating polyose are to get the Radix Isatidis refined polysaccharide of de- protein decolouring, and appearance is in orange
Color clear solution, polysaccharide retention rate 88.12%, albumen removal efficiency 88.68%, percent of decolourization 62.50%.
4) saikoside extracting solution and Banlangen Polysaccharide extracting solution are mixed in 1:1 ratio is corresponding, be used to prepare drug or
Functional food, cosmetics, gained drug or functional food or cosmetics can be capsule, tablet, pill, granule,
Oral solution, syrup, electuary, vina, paste, powder, beverage, injection, emulsifiable paste or lotion etc..It is wherein blue with 60% plate
The mixing of the ratio of root polysaccharide and 40% saikoside is optimal.
Embodiment 3: the Chinese medicine composition for the treatment of whelk and verruca plana
1) radix bupleuri medicine materical crude slice lkg is taken, water 12L steam distillation 6 hours separates volatile oil.Dregs of a decoction 0.05%NaOH,
50% alcohol reflux extracts 2 times, extracts 2 hours every time, recycling design merges with water distillate, water dispersion is added to dissolve, makes water
Solution extension rate is 1:14 (with crude drug meter), and by 10L AB-8 macroporous absorbent resin, adsorption flow rate 4BV/h, resin is stayed
Diameter height compares for 1:8, and applied sample amount is 0.lg/mL (with crude drug meter), and 50% 4 times of ethanol elution resin volume cleans, removes
Miscellaneous flow velocity be 2BV/h, 90% 4 times of ethanol elution resin volume, elution flow rate 2BV/h, collect 90% ethanol eluate, return
Solvent is received, is dried under reduced pressure, as total saponins from radix bupleuri extract.Measuring total saponin content in total saponins from radix bupleuri extract is 65%,
Wherein the sum of the content of radix bupleuri soap back b1, saikoside b2, four kinds of saikoside h, saikosaponin a ingredients are 22%.
2) Radix Isatidis 20g is weighed, 300mL deionized water is added, the extraction of 90C temperature takes, extracts 2 times, each 2h；Merge 2 times
Extracting solution is concentrated under reduced pressure into 100mL and 280mL ethyl alcohol is added, makes concentration of alcohol 70%.10h is stood, alcohol is obtained by filtration in filter paper
400mL deionized water is added with 200mL ethanol washing in hypostasis, and ultrasound is redissolved, and 60mL is concentrated under reduced pressure into, and filters off insoluble matter,
Up to concentration about 0.33g/mL (based on crude drug) Banlangen Polysaccharide liquid.
3) it takes by pretreated macroporous type Weak-acid cation exchange resin, filters off moisture content, weigh 3g and be placed in resins exchange
Device is added the polysaccharide crude liquid that step 2) obtains, is placed in water bath with thermostatic control in the ratio of every gram of resin 20mL Banlangen Polysaccharide crude liquid
In shaking table, 50 DEG C, after 100r/min vibrates 5h, resin is filtered off, the albumen and pigment in separating polyose are to get de- protein decolouring
Radix Isatidis refined polysaccharide, appearance be in orange-yellow clear solution, polysaccharide retention rate 98.85%, albumen removal efficiency 88 80%,
Percent of decolourization 57.55%.
4) saikoside extracting solution and Banlangen Polysaccharide extracting solution are mixed in 7:3 ratio is corresponding, be used to prepare drug or
Functional food, gained drug or functional food can be capsule, tablet, pill, granule, oral solution, syrup, punching
Agent, vina, paste, powder, beverage, injection etc..It is wherein mixed with the ratio of 60% Banlangen Polysaccharide and 40% saikoside
It closes optimal.
Embodiment 4: the Chinese medicine composition for the treatment of whelk and verruca plana
1) radix bupleuri medicine materical crude slice 10kg is taken, water 12L steam distillation 6 hours separates volatile oil.Dregs of a decoction 0.05%NaOH,
50% alcohol reflux extracts 3 times, extracts 1 hour every time, recycling design merges with water distillate, water dispersion is added to dissolve, makes water
Solution extension rate is 1:12 (with crude drug meter), passes through 10L AB-8 macroporous absorbent resin, adsorption flow rate 3BV/h, resin
Column diameter height compares for 1:8, and applied sample amount is 0.1g/mL (with crude drug meter), and 55% 4 times of ethanol elution resin volume cleans, removes
Miscellaneous flow velocity be 2BV/h, 85% 4 times of ethanol elution resin volume, elution flow rate 2BV/h, collect 85% ethanol eluate, return
Solvent is received, is dried under reduced pressure, as total saponins from radix bupleuri extract.Measuring total saponin content in total saponins from radix bupleuri extract is 65%,
Wherein the sum of content of saikoside b1, saikoside b2, four kinds of saikoside h, saikosaponin a ingredients is 25%.
2) Radix Isatidis 20g is weighed, 300mL deionized water is added, the extraction of 90C temperature takes, extracts 2 times, each 2h；Merge 2 times
Extracting solution is concentrated under reduced pressure into 100mL, and 280mL ethyl alcohol is added, makes Z determining alcohol 70%.10h is stood, alcohol is obtained by filtration in filter paper
400mL deionized water is added after 200mL ethanol washing in hypostasis, and ultrasound is redissolved, and 40mL is concentrated under reduced pressure into, and filters off insoluble
Object is to get concentration about 0.50g/mL (based on crude drug) Banlangen Polysaccharide liquid.
3) it takes by pretreated macroporous type Weak-acid cation exchange resin, filters off moisture content, weigh 3g resin and be placed in resin
Exchanger is added the polysaccharide crude liquid that step 2) obtains, is placed in constant temperature in the ratio of every gram of resin 20mL Banlangen Polysaccharide crude liquid
In shaking bath, after 25C, 100r/min vibrate 3h, resin is filtered off, the albumen and pigment in separating polyose are de- to get de- albumen
The Radix Isatidis refined polysaccharide of color, appearance are in orange-yellow clear solution, polysaccharide retention rate 90.33%, albumen removal efficiency
86.58%, percent of decolourization 54.545%.
4) saikoside extracting solution and isatis root extract are mixed in 1:2 ratio, is used to prepare pharmaceutical preparation or function
Property food, cosmetics, gained drug or functional food or cosmetics can be capsule, tablet, pill, granule, oral
Liquid, syrup, electuary, vina, paste, powder, beverage, injection, emulsifiable paste or lotion etc..
The Chinese medicine composition for the treatment of whelk and verruca plana prepared by above-described embodiment 1~4 is respectively used to prepare drug system
Agent is individually used to prepare pharmaceutical preparation as a comparison case with saikoside extract and isatis root extract.The present invention is real
Apply 1~4 Chinese medicine composition of example preparation pharmaceutical preparation 1~2 week of drug effect, comparative example preparation pharmaceutical preparation drug effect 5~
6 weeks, or even without drug effect.
The present embodiment additionally provides the application of the Chinese medicine composition of above-mentioned treatment whelk and verruca plana, utilizes above-mentioned group
Conjunction prepares the medicine for external application of ice unguentum flavum, Cuo health king's liniment etc., and composition additive amount is 10-40%；Cooperate pearl powder preparationization
Cosmetic, composition additive amount are 1-10%, and the effect of oil control and acne removal can be played for oily skin.It is made and is used according to drug
Way and type, dosage have certain deviation.But all dosages are in the range of 1-2g, if illness occur can seriously fit
When 1.5-2 times of dosage of increase.
The clinical testing data of pharmaceutical preparation treatment treatment whelk and verruca plana manufactured in the present embodiment is as follows:
Using the pharmaceutical preparation of composition preparation prepared by the embodiment of the present invention 3, therapeutic effect is as follows, utilizes above-mentioned group
Conjunction prepares ice unguentum flavum medicine for external application, and composition additive amount is 30%；
It is 24 clinical, 16 verruca planas, 8 whelks.Verruca plana patient 16~22 years old, average age 21 years old, wherein male
It 7, female 9, fully recovers 4, effective 8, effective 3, invalid 1.Over the course for the treatment of, only skin lesion in 5 days disappears most fast person
Lose, most slow person after 12 days skin lesion beginning move back, most of patients using skin lesion in 7 days or so all subside.Whelk patient 15~
20 years old, average age 18 years old, wherein male 7, fully recovers 1, effective 6, effective 1 by female 1.Most of patient concentrates on making
There is large area recession with 13 days or so of drug.
It finds over the course for the treatment of, the short person's effect of the course of disease is good, and course of disease elder's effect is poor, and the above patient is using
It is not recurred in 1~2 month afterwards, does not find any side effect also over the course for the treatment of.
Fig. 3 is embodiment 3, and the PMP of Radix Isatidis main component spreads out colour analysis figure, shows the plate in the present invention in Radix Isatidis
Blue root polysaccharide therapeutic effect is obvious.
And existing drug therapy:
Such as, Yi Keer treats verruca plana and needs 20 days or so different degrees of curative effect occur.Tretinoin Ointment in Treatment is flat
Wart needs two months or so different degrees of curative effect occur.
Such as, treatment acne is particular for being adjusted to master within teenager, supplemented by external application.Interior adjust is incretion balance, and hormone is flat
Weighing apparatus.Cooperate tetracycline class oral or Clindamycin Hydrochloride external application for curing, different degrees of curative effect occurs within one month or so.
It should be noted that, in this document, relational terms such as first and second and the like are used merely to a reality
Body or operation are distinguished with another entity or operation, without necessarily requiring or implying between these entities or operation
There are any actual relationship or orders.Moreover, the terms "include", "comprise" or its any other variant are intended to
Cover non-exclusive inclusion, so that the process, method, article or equipment for including a series of elements not only includes that
A little elements, but also including other elements that are not explicitly listed, or further include for this process, method, article or
The intrinsic element of equipment.In the absence of more restrictions, the element limited by sentence "including a ...", not
There is also other identical elements in the process, method, article or apparatus that includes the element for exclusion.
The above embodiments are merely illustrative of the technical solutions of the present invention, rather than its limitations；Although with reference to the foregoing embodiments
Invention is explained in detail, those skilled in the art should understand that: it still can be to aforementioned each implementation
Technical solution documented by example is modified or equivalent replacement of some of the technical features；And these modification or
Replacement, the spirit and scope for technical solution of various embodiments of the present invention that it does not separate the essence of the corresponding technical solution.
Claims (9)
1. a kind of Chinese medicine composition for treating whelk and verruca plana, which is characterized in that mentioned including bupleurum extract and Radix Isatidis
Take object.
2. the Chinese medicine composition for the treatment of whelk and verruca plana as described in claim 1, which is characterized in that the bupleurum extract
Middle saikoside content accounts for the 5~100% of total amount.
3. the Chinese medicine composition for the treatment of whelk and verruca plana as claimed in claim 2, which is characterized in that the saikoside packet
Include saikosaponin a, saikoside c, saikoside d, saikoside b1, saikoside b2, saikoside h it is any in or it is a variety of.
4. the Chinese medicine composition for the treatment of whelk and verruca plana as described in claim 1, which is characterized in that the Radix Isatidis extracts
Object includes Banlangen Polysaccharide.
5. treating the Chinese medicine composition of whelk and verruca plana as described in any one of Claims 1 to 4, which is characterized in that described
The mixed proportion of bupleurum extract and the isatis root extract is 3~7:3~7.
6. treating the preparation method of the Chinese medicine composition of whelk and verruca plana as described in Claims 1 to 5 is any, feature exists
In specific steps are as follows:
S1: the preparation of bupleurum extract, including solvent extraction, filtering, concentration；
The substance of isatis root extract, including solvent extraction, filtering, concentration, purifying；
S2: bupleurum extract and isatis root extract mixing.
7. the preparation method of the Chinese medicine composition for the treatment of whelk and verruca plana as claimed in claim 6, which is characterized in that described
Pass through steam distillation before solvent extraction in the preparation process of bupleurum extract.
8. the preparation method of the Chinese medicine composition for the treatment of whelk and verruca plana as claimed in claim 6, which is characterized in that described
The raw material for extracting bupleurum extract includes any one of stem, leaf, flower spike, fruit, rhizome or radix bupleuri medicine materical crude slice of radix bupleuri or more
Kind.
9. treating the application of the Chinese medicine composition of whelk and verruca plana as described in any one of claim 1~8, feature exists
In the Chinese medicine composition is used to prepare pharmaceutical preparation, functional food or cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810957814.2A CN109157554A (en) | 2018-08-22 | 2018-08-22 | Chinese medicine composition, the preparation method and applications for treating whelk and verruca plana |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810957814.2A CN109157554A (en) | 2018-08-22 | 2018-08-22 | Chinese medicine composition, the preparation method and applications for treating whelk and verruca plana |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109157554A true CN109157554A (en) | 2019-01-08 |
Family
ID=64896504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810957814.2A Pending CN109157554A (en) | 2018-08-22 | 2018-08-22 | Chinese medicine composition, the preparation method and applications for treating whelk and verruca plana |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109157554A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1265310A (en) * | 2000-01-13 | 2000-09-06 | 杨文喜 | Acne treating medicine |
| CN105477199A (en) * | 2014-09-16 | 2016-04-13 | 陈洪波 | Chinese patent medicine for treating liver-depression dryness-heat verruca plana |
-
2018
- 2018-08-22 CN CN201810957814.2A patent/CN109157554A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1265310A (en) * | 2000-01-13 | 2000-09-06 | 杨文喜 | Acne treating medicine |
| CN105477199A (en) * | 2014-09-16 | 2016-04-13 | 陈洪波 | Chinese patent medicine for treating liver-depression dryness-heat verruca plana |
Non-Patent Citations (2)
| Title |
|---|
| 王惠英等: "柴胡注射液湿敷治疗扁平疣23例疗效观察", 《临床医药文献杂志》 * |
| 赵丽: "板蓝根药理作用、临床应用及不良反应", 《河北中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101310751A (en) | Traditional Chinese medicine composition for replenishing qi and blood, preparation method and quality control method thereof | |
| CN103315933A (en) | Traditional Chinese medicine acne-removing extraction liquid and acne-removing paste | |
| KR100611796B1 (en) | Cosmetic composition containing medicinal herbs called sipgeondaebodan and method for preparing the same | |
| CN105168063A (en) | Skin care composition with acne removing effect and preparation method thereof | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| CN104586700A (en) | Vitex negundo linn leaf extract and preparation method as well as application thereof | |
| CN103142916B (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN102716380B (en) | Compound acne-removal cream and production method thereof | |
| CN114794478B (en) | Composition capable of reducing blood pressure, blood lipid and blood sugar and application | |
| WO2023061118A1 (en) | Pharmaceutical composition for improving and treating leukotrichia and/or alopecia and preparation method therefor | |
| CN110787119A (en) | Antibacterial skin-care traditional Chinese medicine composition and preparation method and application thereof | |
| CN105561285A (en) | Ground beeltle biological activity small peptide composition | |
| CN109157554A (en) | Chinese medicine composition, the preparation method and applications for treating whelk and verruca plana | |
| CN105748374A (en) | Traditional Chinese medicine toner with effect of tendering and caring skin | |
| CN100431562C (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| WO2023030041A1 (en) | Type i collagen production accelerant | |
| CN101972334A (en) | Traditional Chinese medicine preparation for preventing and treating infantile eczema and preparation method thereof | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN101147767B (en) | Preparation method of medicinal composition for treating acne | |
| CN105193824B (en) | A kind of ganodenic acid acid activity position and its preparation method and application | |
| CN104771595B (en) | A kind of Chinese medicine composition of strengthen immunity and preparation method thereof | |
| CN103893101A (en) | Ganoderma lucidum and pollen anti-aging cream | |
| CN108686157B (en) | Traditional Chinese medicine composition for preventing and treating blood stasis type nodules of breast, preparation method and pharmaceutical preparation thereof | |
| CN106177082A (en) | A kind of preparation method and application of compound phellodendron bark liquid varnish | |
| CN104510972A (en) | Traditional Chinese medicinal composition for treating asthma and preparation method of traditional Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190108 |